Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Dec;23(6):e13754.
doi: 10.1111/tid.13754. Epub 2021 Nov 12.

Use of anti-CMV immunoglobulins in lung transplant recipients: The French experience

Roy Charlotte  1 , Parquin François  2 , Messika Jonathan  3 , Boussaud Véronique  4 , Brugière Olivier  1 , Degot Tristan  5 , Feuillet Séverine  6 , Lepavec Jérôme  6 , Tissot Adrien  7 , Dromer Claire  8 , Burnet Espérie  4 , Camps Eve  9 , Roux Antoine  1   10
Affiliations
Multicenter Study

Use of anti-CMV immunoglobulins in lung transplant recipients: The French experience

Roy Charlotte et al. Transpl Infect Dis. 2021 Dec.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Transpl Infect Dis. 2022 Jun;24(3):e13824. doi: 10.1111/tid.13824. Epub 2022 Mar 25. Transpl Infect Dis. 2022. PMID: 35338573 No abstract available.

Abstract

Rational: Pending the authorization of new anti-CMV drugs with fewer adverse effects, exploring the possibilities offered by CMV immunoglobulins (CMVIG) seems necessary. In France, access to CMVIG requires official authorization by the national Health authority and is restricted to second line rescue therapy for CMV infection/disease. The aim of this multicenter retrospective study is to describe the indications and clinical situations that justified its use in France.

Methods: A multicenter retrospective study included 22 lung transplant patients over a 3-year period. Data on clinical indication, tolerance and efficacy were collected.

Results: The main indication for CMVIG initiation, which was documented in 17 of them (82%) was complex clinical situations resulting from side effects to antiviral drug. CMVIG indication was documented as treatment for 15 patients (68%) and as a secondary prophylaxis for 7 patients (32%). Only one side effect (pruritus during infusion with no anaphylactic symptoms) attributable to CMVIG was reported. After CMVIG initiation, no recurrence of infection or disease was observed during a median follow-up of 174 (12-682) days after treatment initiation for respectively 68% and 66% of the patients.

Conclusion: This study describes an unusual indication of CMVIG use as a last resort treatment in complex situations, based on clinical needs. CMVIG could be useful to change the course of CMV infection with minimal adverse effects or comorbidity.

Keywords: CMV; CMVIG; alternative therapeutics; hematological toxicity; lung transplant,  rescue treatment.

PubMed Disclaimer

References

REFERENCES

    1. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13512.
    1. Natori Y, Alghamdi A, Husain S, et al. Clinical predictors of progression and clearance of low-level CMV DNAemia in solid organ transplant recipients. Transpl Infect Dis. 2020;22:e13207.
    1. Mitsani D, Nguyen MH, Kwak EJ, et al. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. J Heart Lung Transplant. 2010;29:1014-1020.
    1. Johansson I, Mårtensson G, Nyström U, Nasic S, Andersson R. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients. BMC Infect Dis. 2013;13:582.
    1. Palmer SM. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152:761-769.

Publication types

MeSH terms